Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-MEMRI Trial
NCT04591639Completed
- Sponsor
- University of Edinburgh
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dapagliflozin in heart failure (HF) (2 arms), sponsored by University of Edinburgh. Primary endpoint: Rate of change in myocardial T1 values with manganese enhanced cardiac MRI at 6 months. Started Aug 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04591639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591639.